Hospital admissions due to infections in the national population of people with multiple sclerosis on disease-modifying therapies: Real-world data from NHS England

被引：0
|
作者：
Garjani, Afagh [1 ,2 ]
Osborne, Nick [3 ]
Law, Graham [4 ]
Nightingale, Matthew [3 ]
Evangelou, Nikos [1 ,2 ]
机构：
[1] Univ Nottingham, Sch Med, Mental Hlth & Clin Neurosci Acad Unit, Nottingham, England
[2] Nottingham Univ Hosp NHS Trust, Neurol Clin, Nottingham, England
[3] NHS Arden & Greater East Midlands Commissioning S, Leicester, Leics, England
[4] Univ Lincoln, Sch Hlth & Social Care, Coll Hlth & Sci, Lincoln, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O091/2549
引用
收藏
页码：86 / 87
页数：2
相关论文
共 50 条
  • [41] Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA
    Araujo, Lita
    Kyatham, Srikanth
    Bzdek, Kristen G.
    Higuchi, Keiko
    Greene, Nupur
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (01)
  • [42] Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study
    Miele, Giuseppina
    Cepparulo, Simone
    Abbadessa, Gianmarco
    Lavorgna, Luigi
    Sparaco, Maddalena
    Simeon, Vittorio
    Guizzaro, Lorenzo
    Bonavita, Simona
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [43] REAL-WORLD OUTCOMES AND MEDICATION ADHERENCE TO DISEASE MODIFYING THERAPIES (DMTS) AMONG PATIENTS WITH MULTIPLE SCLEROSIS (MS)
    Grassi, D. M.
    Graham, J.
    Ye, X.
    Maeng, D.
    Frusciante, K.
    Nathanson, D. C.
    Burton, M.
    Wright, E.
    Gomes, J.
    Bao, Y.
    VALUE IN HEALTH, 2018, 21 : S203 - S203
  • [44] The CXCL13 index biomarker predicts success or failure of moderate-efficacy disease-modifying therapies in multiple sclerosis; A real-world study
    Pachner, Andrew R.
    Pike, Steven C.
    Smith, Andrew D.
    Gilli, Francesca
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2025, 95
  • [45] Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
    AlRuthia, Yazed
    Balkhi, Bander
    Alkhalifah, Sahar Abdullah
    Aljarallah, Salman
    Almutairi, Lama
    Alanazi, Miteb
    Alajlan, Abdulmalik
    Aldhafiri, Suliman M.
    Alkhawajah, Nuha M.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (24)
  • [46] Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
    Lita Araujo
    Svend S. Geertsen
    Allen Amedume
    Keiko Higuchi
    Janneke van Wingerden
    Neurology and Therapy, 2022, 11 : 1735 - 1748
  • [47] Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
    Araujo, Lita
    Geertsen, Svend S.
    Amedume, Allen
    Higuchi, Keiko
    van Wingerden, Janneke
    NEUROLOGY AND THERAPY, 2022, 11 (04) : 1735 - 1748
  • [48] Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS
    Crayton, Heidi
    Steingo, Brian
    Huang, Deren
    Meng, Xiangyi
    Schofield, Lesley
    Johnson, Kristen
    Tenenbaum, Nadia
    NEUROLOGY, 2016, 86
  • [49] Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience-Reply
    Roos, Izanne
    Kalincik, Tomas
    JAMA NEUROLOGY, 2024, 81 (01) : 87 - 88
  • [50] A Real-World Study of Disease-Modifying Drug Treatment Patterns in US Patients with Multiple Sclerosis Newly Initiating Treatment
    Nicholas, Jacqueline
    Edwards, Natalie C.
    Harlow, Danielle
    Phillips, Amy
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 20 - 20
12345